Clinical trial · Interventional
Acupuncture Versus Sham for Radiotherapy-Induced Emesis
Acupuncture Compared To Sham With a Placebo-Needle in Radiotherapy-Induced Nausea - a Randomised Controlled Study
NCT00621660CI-TRIAL-00001163completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate if acupuncture prevents or reduces nausea or vomiting during radiotherapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nausea | — | UNRESOLVED | — |
| Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Procedure | — | UNRESOLVED |
| Sham | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Acupuncture
- interventionNames
- Procedure: Acupuncture
- type
- PLACEBO_COMPARATOR
- label
- Sham
- interventionNames
- Procedure: Sham
Primary outcomes (1)
- measure
- Number of patients with at least one episode of nausea during the whole radiotherapy treatment period
- timeFrame
- The radiotherapy treatment period (md 5 weeks)
Secondary outcomes (1)
- measure
- Secondary outcome measures are the summed number of days with nausea, intensity of nausea, number of patients and summed number of days with vomiting, belief in the antiemetic effects and interest in receiving needling in the future
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients of at least 18 years of age * with gynaecologic-, anal-, rectal-, colon-, ventricle-, pancreatic- or testicular tumours * willing to give their informed consent * able to take part in the entire treatment and data collection procedure * had planned radiation over an abdominal and/or pelvic field (with or without concomitant chemotherapy) with the volume of at least 800 cm3 and a dose of at least 25 Gy. Exclusion Criteria: * use of antiemetic treatment or persistent nausea within 24 hours prior to the start of radiotherapy * ever received acupuncture against nausea, or during the last year received acupuncture for any indication.
References
Publications (3)
- DERIVEDEfverman A, Kristofferzon ML. A Basis for Strengthening Coping Strategies and Treatment Expectations in Patients Undergoing Emetogenic Pelvic-Abdominal Radiotherapy: A Longitudinal Study. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241281329. doi: 10.1177/15347354241281329. PMID 39300870
- DERIVEDBlom K, Efverman A. Sleep During Pelvic-Abdominal Radiotherapy for Cancer: A Longitudinal Study With Special Attention to Sleep in Relation to Nausea and Quality of Life. Cancer Nurs. 2021 Jul-Aug 01;44(4):333-344. doi: 10.1097/NCC.0000000000000826. PMID 32371667
- DERIVEDEnblom A, Lekander M, Hammar M, Johnsson A, Onelov E, Ingvar M, Steineck G, Borjeson S. Getting the grip on nonspecific treatment effects: emesis in patients randomized to acupuncture or sham compared to patients receiving standard care. PLoS One. 2011 Mar 23;6(3):e14766. doi: 10.1371/journal.pone.0014766. PMID 21448267